Find disease awareness content and relevant supporting materials
The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective.
Panobinostat is an oral pan-histone deacetylase inhibitor developed by Novartis. Panobinostat acts via epigenetic modification and inhibition of the aggresome pathway.
High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
This update covers recommendations for glioblastoma; anaplastic astrocytoma, oligoastrocytoma and oligodendroglioma; and diffuse glioma. The recommendations cover clinically relevant problems in: diagnosis and pathology...
Phase I/II dose-escalation study of oral administration of the Pan-Histone Deacetylase (HDAC) Inhibitor S 78454 in Hodgkin�s Disease, non-Hodgkin Lymphoma and Chronic Lymphocytic Leukaemia
Phase I part:� - To assess the MTD and the dose-limiting toxicities (DLTs).� Phase II part: - To assess the objective response rate...
Brain invasion in meningiomas-clinical considerations and impact of neuropathological evaluation: a systematic review.
With the release of the 2016 edition of the WHO Classification of Central Nervous System Tumors, brain invasion in meningiomas has been added as a stand-alone criterion for atypia and can therefore impact grading and indirectly adjuvant therapy.
The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma.
The therapeutic armamentarium for multiple myeloma has recently benefited from the addition of several new agents (including second-generation proteasome inhibitors, monoclonal antibodies and histone deacetylase inhibitors).
Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients.
Embryonal tumor with multilayered rosettes (ETMR) is a rare and aggressive embryonal brain tumor that solely occurs in infants and young children and has only recently been recognized as a separate brain tumor entity...